Trials / Completed
CompletedNCT00198380
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtype in the 2004 WHO classification. Surgery is the best therapy for resectable tumors since the effectiveness of chemotherapy is disappointing. In the advanced P-ADC diffuse/multifocal types of BAC, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib) have shown promise, with some rapid, dramatic responses, possibly reflecting specific molecular differences from other non-small cell lung carcinomas.
Detailed description
We therefore conducted a French multicentric phase II trial (IFCT 0401) to evaluate activity and tolerance of gefitinib (250 mg/day) administered as first line treatment in patients with non-resectable P-ADC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | Gefitinib 250 mg/day, until progression or severe toxicity |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2008-12-01
- Completion
- 2009-12-01
- First posted
- 2005-09-20
- Last updated
- 2024-03-08
Locations
11 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00198380. Inclusion in this directory is not an endorsement.